TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02163733

Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablets
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD9291 tablets
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: Allocated breakfast prior to dosing with 80mg AZD9291 tablet

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
Study: NCT01402141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chungkookjang
Description: Chungkookjang(35g/say)for 12 weeks
Study: NCT03907280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T3)
Description: Solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T3)
Description: Solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T3)
Description: Solution for inhalation
Study: NCT04385446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane transplantation was used as covering material during pterygium surgery.
Study: NCT00174642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: One daily injection in the evening. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: One daily injection in the evening. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: One daily injection in the evening. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Given immediately before each of the three main meals. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Given immediately before each of the three main meals. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Given immediately before each of the three main meals. 100 U/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At same dosages as the previous treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At same dosages as the previous treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At same dosages as the previous treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin secretagogue
Description: sulfonylurea or glinide
Study: NCT01508273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Website access given that allows participant to track exercise behavior and help to set goals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Website
Description: Website access given that allows participant to track exercise behavior and help to set goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise DVD
Description: Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Report Assessments
Description: Self-report assessments given about quality of life and physical assessments of balance and coordination.
Study: NCT03828123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suspension of human autologous MSC 3P in 1.5 ml
Description: Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
Study: NCT01402141

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(35g/day) for 12 weeks
Study: NCT00828984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol 3350-based oral osmotic laxative
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol 3350-based oral osmotic laxative
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05079074

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA testing
Description: ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
Study: NCT03212157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Description: Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Description: Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Description: Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
Study: NCT03214367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT01633879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio-CD parent education
Description: audio CD stories in English and Spanish that support positive parenting practices
Study: NCT04805801

Intervention type: DRUG
Intervention: Emicizumab subcutaneous injection
Description: Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
Study: NCT01633879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health and success parent and school
Description: Parenting education and school intervention
Study: NCT04238364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EI-1071
Description: EI-1071 Tablet(s)
Study: NCT00774306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
Study: NCT02551471

Intervention type: OTHER
Intervention: Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)
Description: This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.
Study: NCT04238364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet(s)
Study: NCT01930357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine Serum Free (VRVg)
Description: 0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
Description: 0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
Study: NCT03676179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patella denervation
Description: patella denervation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patella non-denervation
Description: patella non-denervation
Study: NCT01654432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Blocks (PVB)
Study: NCT02366637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally inhaled placebo twice a day (BID) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03715455
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
Study: NCT02086149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
Study: NCT03887026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Norketotifen oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Norketotifen oral capsule
Study: NCT04128644

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thoughts & health
Description: 12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
Study: NCT03887026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT01727479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ribose
Description: After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02551471

Intervention type: OTHER
Intervention: Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)
Description: This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries.

Intervention type: OTHER
Intervention: MDT (Multidisciplinary team) meeting observation
Description: 3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading).
Study: NCT02084732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: drug
Study: NCT02598661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Intravenous injection.
Study: NCT04128644

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Baseline questionnaires and follow up assessments, intervention as usual, Student Health

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Baseline questionnaires and follow up assessments, intervention as usual, Student Health
Study: NCT02837978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
Study: NCT02598661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to Imetelstat will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to Imetelstat will be administered.
Study: NCT04801680

Intervention type: DEVICE
Intervention: Mpact 3D metal cup
Description: Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
Study: NCT02837978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
Study: NCT05029323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fast HUTT
Description: Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional HUTT
Description: Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
Study: NCT01371578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5885 tablet
Description: 30 mg active tablet
Study: NCT04432701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: proactive extubation
Description: when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
Study: NCT03748290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75 mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT01371578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451 tablet
Description: two active 100 mg tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: peginterferon alfa-2a (solution for injection) 180 µg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Study: NCT03644095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex® SE
Description: Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicks Cough Syrup for Chesty Coughs
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
Study: NCT03080181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.6 MG/ML
Description: The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
Study: NCT00788528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 (velneperit)
Description: Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
Study: NCT04182750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Description: The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use.
Study: NCT03198702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The injection is mimed, the procedure is the same as the botulinum toxin injection.
Study: NCT00130520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg every two weeks IV-bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150mg daily by mouth-erlotinib
Study: NCT03918863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Same protocol of exercises of the other group, without association of electrical stimulation.
Study: NCT03788681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: oral estradiol  estradiol valerate  (Cyclo-Progynova)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study: NCT02257359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban
Description: Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
Study: NCT00621179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate in depot suspension
Description: Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate in depot suspension
Description: Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention